Prostate cancer and PSMA-targeted therapy
Clinical research in high-risk prostate cancer, very high-risk prostate cancer, and localized or locally advanced disease includes interest in PSMA PET, radioligand therapy, and preoperative treatment strategies for patients considered for radical prostatectomy or curative-intent radiotherapy.
- PSMA PET imaging
- Lu-PSMA radioligand therapy
- Neoadjuvant prostate cancer treatment
The sponsor also studies biomarker-informed treatment selection in prostate cancer and imaging-guided approaches for defining local therapy.
Non-small-cell lung cancer and thoracic oncology
Research activity includes resectable non-small-cell lung cancer, EGFR-mutated lung cancer, and stage III disease, with attention to immunotherapy, antibody-based treatment, and multimodal regimens around surgery and chemoradiotherapy.
- Neoadjuvant immunotherapy
- EGFR-mutated NSCLC
- Multimodality lung cancer treatment
These studies cover both early-stage and locally advanced thoracic malignancies, including settings where surgery remains part of the treatment pathway.
Melanoma and biomarker-guided immunotherapy
The sponsor is involved in stage II melanoma research after surgery, with emphasis on adjuvant immunotherapy and biomarker-based risk stratification to identify patients with a higher likelihood of recurrence.
- Adjuvant nivolumab
- Relapse-free survival
- Biomarker selection
This area reflects interest in postoperative management of cutaneous melanoma and in refining patient selection for systemic treatment.
Gastrointestinal cancers and liver metastases
Clinical studies extend to gastrointestinal malignancies, including colorectal cancer, gastric cancer, pancreatic cancer, oesophageal cancer, cholangiocarcinoma, and hepatocellular carcinoma, as well as colorectal liver metastases.
- FAPI PET imaging
- Preoperative immunotherapy
- Resectable liver metastases
Research in this domain includes imaging approaches for tumour detection and treatment strategies in surgically managed metastatic disease.
Transplant medicine and pediatric nephrology
Additional work focuses on paediatric kidney transplant recipients, with interest in tacrolimus use, pharmacokinetics, and maintenance treatment after transplantation.
- Paediatric kidney transplantation
- Tacrolimus therapy
- Post-transplant immunosuppression
This area addresses therapeutic management in children requiring ongoing transplant-related care.
